TLRY Tilray

Tilray Brands Launches Charlotte’s Web™ CBD Gummies in Canada

Tilray Brands Launches Charlotte’s Web™ CBD Gummies in Canada

TORONTO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company, announced the launch of new Charlotte's Web (TSX: CWEB) (OTCQX: CWBHF) CBD gummies in Canada. Designed specifically for daily CBD consumers, Charlotte’s Web CBD Rest Gummies and CBD Life Gummies offer an easy, delicious, and convenient way to incorporate CBD into your wellness routine.

The new gummies are available in a 30-pack bottle with two distinct flavors: Berry & Fruit and Turmeric & Ginger. Each gummy contains 25mg of premium CBD, ensuring a consistent and enjoyable experience.

Crafted in the pristine northern Okanagan Valley of British Columbia, these gummies leverage Charlotte’s Web’s proprietary hemp genetics. They feature full-spectrum CBD hemp extract, meticulously blended with functional herbs and botanical supplements to provide synergistic support for targeted wellness benefits.

Charlotte’s Web Rest Gummies in Berry & Fruit is specially formulated to support your wind-down routines and is a great way to reward yourself post-workout, pre-bedtime, or anywhere between for the ultimate way to rest or reset after a long day.

Charlotte’s Web Life Gummies in Turmeric & Ginger are specifically formulated to support an active lifestyle from day to night, helping you conquer your life’s busiest days.

The Charlotte’s Web CBD Rest and Life CBD gummies are available at select cannabis retailers across Ontario. They will become available through the Tilray Medical website and soon to be in select provinces and retailers this October and November.

About Charlotte’s Web

Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) is a  headquartered in Louisville, Colorado, is the market leader in innovative whole-plant full-spectrum hemp extract wellness products. Known as The World’s Most Trusted Hemp Extract™, Charlotte’s Web is the official CBD of Major League Baseball©. Charlotte's Web branded premium quality products start with proprietary hemp genetics that are North American farm-grown and contain naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, terpenes, flavonoids, and other beneficial compounds. In Canada, Charlotte’s Web is produced in accordance with Health Canada Processing and Cultivation license by Aphria Inc., a subsidiary of Tilray Brands, Inc.

© Major League Baseball trademarks and copyrights are used with permission of Major League Baseball. Visit MLB.com.

For more information on Charlotte’s Web, visit

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. 

For more information on how we are elevating lives through moments of connection, visit  and follow @Tilray on all social platforms. 

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.



Media Contact:

Investor Contact: 



EN
07/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tilray

 PRESS RELEASE

Tilray erweitert den pharmazeutischen Zugang im Vereinigten Königreich...

Tilray erweitert den pharmazeutischen Zugang im Vereinigten Königreich durch eine strategische Vereinbarung mit Smartway Pharmaceuticals CC-Pharma-Vereinbarung fördert das Wachstum von Tilray im Vereinigten Königreich und stärkt den Vertrieb über Apotheken- und Krankenhauskanäle NEW YORK und LONDON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), gab heute bekannt, dass ihr europäisches pharmazeutisches Vertriebsunternehmen CC Pharma eine strategische Vereinbarung mit , einem führenden pharmazeutischen Vertriebspartner...

 PRESS RELEASE

Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni g...

Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni grâce à un accord stratégique avec Smartway Pharmaceuticals L’accord avec CC Pharma renforce la croissance de Tilray au Royaume-Uni, consolidant sa distribution auprès des pharmacies et des hôpitaux NEW YORK et LONDRES, 13 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la division pharmaceutique de Tilray Brands, Inc. (Nasdaq : TLRY ; TSX : TLRY), a annoncé aujourd'hui que son activité de distribution pharmaceutique européenne, CC Pharma, a conclu un accord stratégique avec , un partenaire de distribution pharmaceutique...

 PRESS RELEASE

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement wi...

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals CC Pharma Agreement Bolsters Tilray’s UK Growth, Strengthening Distribution to Pharmacy and Hospital Channels NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), today announced that its European pharmaceutical distribution business, CC Pharma, has entered into a strategic agreement with , a leading UK-based pharmaceutical distribution partner, to expand the availability of pharmaceutical products...

 PRESS RELEASE

CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in De...

CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in Deutschland ausgezeichnet Die Auszeichnung würdigt CC Pharma als innovativen Marktführer und vertrauenswürdigen Partner auf dem europäischen Pharmamarkt DENSBORN, Deutschland, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), gab heute bekannt, dass , ihr europäischer Pharmahändler, zu einem der ernannt wurde. Hierbei handelt es sich um eine der renommiertesten und unabhängigsten Auszeichnungen für Innovation bei kleinen und mittleren Unternehmen des La...

 PRESS RELEASE

CC Pharma, filiale de Tilray, figure parmi le classement TOP 100 Innov...

CC Pharma, filiale de Tilray, figure parmi le classement TOP 100 Innovator en Allemagne Cette distinction récompense CC Pharma dans son rôle de leader de l’innovation et de partenaire de référence du marché pharmaceutique européen DENSBORN, Allemagne, 04 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la division pharmaceutique de Tilray Brands, Inc. (Nasdaq : TLRY ; TSX : TLRY), a annoncé aujourd’hui que , son entreprise européenne de distribution pharmaceutique, a été nommée au , l’une des distinctions indépendantes les plus prestigieuses du pays en matière d’innovation parmi les petite...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch